Clinical Trials Logo

Non Alcoholic Fatty Liver clinical trials

View clinical trials related to Non Alcoholic Fatty Liver.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03953456 Terminated - Clinical trials for Non-Alcoholic Fatty Liver

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Start date: August 16, 2019
Phase: Phase 2
Study type: Interventional

This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an adult NAFL population after 6 weeks of treatment with a 4-week wash-out period. This study will achieve mechanistic information about the mode of action of Elafibranor on the (lipid) metabolism in the human fatty liver